The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).
Edward B. Garon
Research Funding - Novartis
Teresa Moran
No relevant relationships to disclose
Fabrice Barlesi
Honoraria - Novartis; Novartis
Research Funding - Novartis; Novartis
Leena Gandhi
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
Sang-We Kim
No relevant relationships to disclose
Harry J.M. Groen
No relevant relationships to disclose
Benjamin Besse
No relevant relationships to disclose
Egbert F Smit
No relevant relationships to disclose
Dong-Wan Kim
No relevant relationships to disclose
Mikhail Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Emin Avsar
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Stuart Bailey
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Enriqueta Felip
No relevant relationships to disclose